John Willis
Rheumatology · Dallas, TXNPI 1093730160
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 567 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AbbVie at 30.4% of the total. Reporting peaked in 2021 at $3,108 and has fallen 98.7% since, to $42 in 2024.
Across 567 payments — averaging $17.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Amgen$2K
- Novartis$2K
- GSK$360
- Pfizer$316
- Aurinia Pharma U.S., Inc.$258
- plus $2K from 24 others
What the payments were for
- Food & beverage$9,648100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 153 | $2,934 |
| Amgen(2 entities) | 110 | $1,918 |
| Novartis | 128 | $1,749 |
| GSK | 25 | $360 |
| Pfizer | 18 | $316 |
| Aurinia Pharma U.S., Inc. | 14 | $258 |
| UCB, Inc. | 15 | $252 |
| AstraZeneca(2 entities) | 12 | $222 |
| Mallinckrodt Hospital Products Inc. | 8 | $208 |
| Lilly USA, LLC | 14 | $195 |
| E.r. Squibb & Sons, L.L.C. | 12 | $191 |
| Johnson & Johnson(2 entities) | 9 | $183 |
| Genentech USA, Inc. | 11 | $178 |
| Bristol Myers Squibb | 7 | $147 |
| Mallinckrodt Enterprises LLC | 5 | $129 |
| Bioventus LLC | 3 | $72 |
| Sanofi | 3 | $61 |
| Organon | 6 | $34 |
| Ultragenyx Pharmaceutical Inc. | 2 | $31 |
| ANI Pharmaceuticals, Inc. | 1 | $28 |
| Merck | 2 | $24 |
| Radius Health, Inc. | 1 | $23 |
| Hikma Pharmaceuticals USA | 1 | $23 |
| Sobi, Inc | 1 | $23 |
| Gilead | 1 | $20 |
| Antares Pharma, Inc. | 1 | $19 |
| Pacira Therapeutics, Inc. | 1 | $18 |
| Boston Scientific | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Avanos Medical | 1 | $14 |
How this compares
$9,664 in reported general payments places this provider in the 65th percentile of 512 rheumatology providers in Texas.
Other rheumatology in Dallas
- John CushDallas$3.7M
- Zoran KurepaDallas$483K
- Giovanni GeslaniDallas$415K
- Dianne PetroneDallas$401K
- Stanley CohenDallas$318K
- Joanna GeslaniDallas$242K
- Sharad LakhanpalDallas$229K
- Iftikhar ChowdhryDallas$226K
- Srilatha KothandaramanDallas$140K
- Leyka BarbosaDallas$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.